SYK and ZAP70 kinases in lymphocyte selection
SYK and ZAP70 kinases in lymphocyte selection
批准号:
10557882
负责人:
Eric Meffre
金额:
$61.73万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-02-01 至 2027-01-31
关键词:
AblationAccelerationAcuteAllelesAntibodiesAutoantibodiesAutoimmune DiseasesB lymphoid malignancyB-Cell Acute Lymphoblastic LeukemiaB-Cell Antigen ReceptorB-Cell DevelopmentB-Cell LymphomasB-Cell NeoplasmB-LymphocytesBLNK geneBiological MarkersCalcium SignalingCell DeathCell ProliferationCell SurvivalCellsChronic Lymphocytic LeukemiaClonal DeletionClone CellsDevelopmentDominant-Negative MutationEngineeringEtiologyEvolutionFlareFrequenciesGeneticGenetic studyHumanImpairmentKnock-inLymphocyteMalignant - descriptorMediatingMusOncogenesOncogenicOnset of illnessOutputPIK3CG genePathologicPatientsPeripheralPhosphoric Monoester HydrolasesPhosphotransferasesPreclinical TestingProductionProtein AnalysisReceptor SignalingReportingReverse Transcriptase Polymerase Chain ReactionRheumatoid ArthritisSYK geneSignal TransductionStructure of germinal center of lymph nodeSystemic Lupus ErythematosusT-Cell DevelopmentT-Cell LymphomaT-Cell ReceptorT-LymphocyteTestingZAP-70 Geneanaloganergyautoreactive B cellautoreactivitycell transformationhumanized mouseinducible gene expressionloss of functionmouse modelmutantnoveloptogeneticspatient derived xenograft modelpharmacologicphosphoproteomicspremalignantpressurepreventpromoterremote controlsegregationsingle cell proteinssmall molecule inhibitorstoichiometry
中文摘要
摘要
虽然B细胞承受着消除自身反应和癌前克隆的巨大选择压力,
我们将SYK确定为中央激酶,以设定负选择的阈值。SYK及其高级化
同源亲缘ZAP70启动B细胞受体和T细胞受体信号转导
分别为T淋巴细胞。尽管这两个激酶几乎完全相同,并且服务类似
功能,它们在B细胞和T细胞中的表达在整个进化过程中是严格分离的。鉴于
分离两种蛋白的原因不明,Syk和ZAP70的异常共表达
以前报道过B细胞慢性淋巴细胞白血病(CLL)和外周T细胞淋巴瘤
(PTCL)。我们的研究小组最近证实,ZAP70的异常表达是Pre-Pre的常见特征。
生发中心(GC)B细胞恶性肿瘤(B-ALL、CLL、MCL;SADRAS等人,Mol Cell 2021)。在遗传方面
B-ALL和B-CLL小鼠模型,诱导共表达ZAP70加速疾病发病,而
基因缺失阻碍了恶性转化。同样,ZAP70的诱导表达在
早期B细胞发育颠覆自身反应性B细胞负选择促进弥漫性
自身抗体的产生。
从机制上讲,ZAP70与SYK竞争,对SYK依赖的SYK产生显性负向作用
钙离子--信号转导。通过占用而不是磷酸化BLNK、BTK和PLC2底物
通过钙信号转导,ZAP70显著降低了自主钙振荡的频率。快地
在SYK(4.5 MHz)单独存在的情况下,振荡由NFATC1解码,并导致无能和
细胞死亡。相反,在ZAP70(0.25 MHz)存在下,缓慢的钙振荡促进选择性
激活核因子-B和B细胞的存活和增殖。
我们在这里测试了一个中心假设,即B细胞感知A细胞下游的病理性信号
自身反应性bcr或通过SYK依赖的高频钙离子-转化癌基因-
震荡。在高频下,钙离子振荡激活NFATC1启动B细胞无能和克隆性
删除。相反,ZAP70可减缓钙离子振荡以激活核因子-B,而不是NFATC1.
使自身反应性和癌前B细胞克隆持续存在,并最终导致自身免疫
疾病或GC前B细胞恶性肿瘤。
我们提出三个目标:(1)阐明ZAP70延缓SYK-
依赖的高频钙振荡,以(2)确定ZAP70的共表达如何颠覆
自身免疫性疾病中自身反应性B细胞的阴性选择和(3)揭示ZAP70是如何
使癌前B细胞发生致癌信号和明显的恶变。
英文摘要
ABSTRACT
While B-cells are under intense selective pressure to eliminate autoreactive and pre-malignant clones,
we identified SYK as central kinase to set the thresholds for negative selection. SYK and its highly
homologous relative ZAP70 initiate B-cell receptor (BCR) and T-cell receptor (TCR) signaling in B- and
T-lymphocytes, respectively. Even though the two kinases are almost identical and serve analogous
functions, their expression in B- and T-cells is strictly segregated throughout evolution. Whereas the
reason for separation of the two kinases is not known, aberrant coexpression of Syk and Zap70 was
previously reported in B-cell chronic lymphocytic leukemia (CLL) and in peripheral T-cell lymphoma
(PTCL). Our group recently demonstrated that aberrant ZAP70 expression is a common feature in pre-
germinal center (GC) B-cell malignancies (B-ALL, CLL, MCL; Sadras et al., Mol Cell 2021). In genetic
mouse models for B-ALL and B-CLL, inducible coexpression of Zap70 accelerated disease onset, while
genetic deletion impaired malignant transformation. Likewise, inducible expression of Zap70 during
early B-cell development subverted negative selection of autoreactive B-cells to promote pervasive
autoantibody production.
Mechanistically, ZAP70 competes with SYK and exerts a dominant-negative effect on SYK-dependent
Ca2+-signaling. By occupying but not phosphorylating BLNK, BTK and PLC2 substrates upstream of
calcium signaling, ZAP70 dramatically reduces the frequency of autonomous Ca2+-oscillations. Fast
oscillations in the sole presence of SYK (4.5 mHz) are decoded by NFATC1 and result in anergy and
cell death. In contrast, slow Ca2+-oscillations in the presence of ZAP70 (0.25 mHz) promote selective
activation of NF-B and B-cell survival and proliferation.
We test here the central hypothesis that B-cells sense pathological signaling downstream of an
autoreactive BCR or a transforming oncogene through SYK-dependent high-frequency Ca2+-
oscillations. At high frequencies, Ca2+-oscillations activate NFATC1 to initiate B-cell anergy and clonal
deletion. Conversely, ZAP70 slows down Ca2+-oscillations to activate NF-B instead of NFATC1 and
enables autoreactive and premalignant B-cell clones to persist and eventually give rise to autoimmune
disease or pre-GC B-cell malignancies.
We are proposing three Aims to (1) elucidate the mechanisms by which ZAP70 slows down SYK-
dependent high-frequency Ca2+-oscillations, to (2) determine how coexpression of ZAP70 subverts
negative selection of autoreactive B-cells in autoimmune disease and (3) to uncover how ZAP70
enables oncogenic signaling and overt malignant transformation of pre-malignant B-cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Elucidating the immunology of autoantibody formation and function in COVID-19
-
批准号:10639707
-
项目类别:
-
资助金额:$75.07万
-
财政年份:2023
-
负责人:Eric Meffre
-
依托单位:
SYK and ZAP70 kinases in lymphocyte selection
-
批准号:10467215
-
项目类别:
-
资助金额:$61.73万
-
财政年份:2022
-
负责人:Eric Meffre
-
依托单位:
Impact of regulatory T cells on human peripheral B cell tolerance
-
批准号:8424216
-
项目类别:
-
资助金额:$20.79万
-
财政年份:2012
-
负责人:Eric Meffre
-
依托单位:
Impact of regulatory T cells on human peripheral B cell tolerance
-
批准号:8302578
-
项目类别:
-
资助金额:$24.88万
-
财政年份:2012
-
负责人:Eric Meffre
-
依托单位:
Loss of B cell tolerance in rheumatoid arthritis
-
批准号:8091761
-
项目类别:
-
资助金额:$19.23万
-
财政年份:2010
-
负责人:Eric Meffre
-
依托单位:
Autoreactive B Cell Development in Autoimmune Disease
-
批准号:7687682
-
项目类别:
-
资助金额:$20.22万
-
财政年份:2009
-
负责人:Eric Meffre
-
依托单位:
Loss of B Cell Tolerance in Rheumatoid Arthritis
-
批准号:8811079
-
项目类别:
-
资助金额:$41.63万
-
财政年份:2006
-
负责人:Eric Meffre
-
依托单位:
Loss of B Cell Tolerance in Rheumatoid Arthritis
-
批准号:8586459
-
项目类别:
-
资助金额:$41.63万
-
财政年份:2006
-
负责人:Eric Meffre
-
依托单位:
Loss of B Cell Tolerance in Rheumatoid Arthritis
-
批准号:8968799
-
项目类别:
-
资助金额:$41.63万
-
财政年份:2006
-
负责人:Eric Meffre
-
依托单位:
Loss of B cell tolerance in rheumatoid arthritis
-
批准号:7446808
-
项目类别:
-
资助金额:$41.67万
-
财政年份:2006
-
负责人:Eric Meffre
-
依托单位:
Loss of B Cell Tolerance in Rheumatoid Arthritis
-
批准号:8237551
-
项目类别:
-
资助金额:$41.43万
-
财政年份:2006
-
负责人:Eric Meffre
-
依托单位:
Loss of B cell tolerance in rheumatoid arthritis
-
批准号:7642270
-
项目类别:
-
资助金额:$39.41万
-
财政年份:2006
-
负责人:Eric Meffre
-
依托单位:
Loss of B cell tolerance in rheumatoid arthritis
-
批准号:7252482
-
项目类别:
-
资助金额:$42.36万
-
财政年份:2006
-
负责人:Eric Meffre
-
依托单位:
Loss of B cell tolerance in rheumatoid arthritis
-
批准号:7137361
-
项目类别:
-
资助金额:$43.41万
-
财政年份:2006
-
负责人:Eric Meffre
-
依托单位:
Loss of B Cell Tolerance in Rheumatoid Arthritis
-
批准号:8373885
-
项目类别:
-
资助金额:$39.06万
-
财政年份:2006
-
负责人:Eric Meffre
-
依托单位:
Loss of B cell tolerance in rheumatoid arthritis
-
批准号:7935214
-
项目类别:
-
资助金额:$39.02万
-
财政年份:2006
-
负责人:Eric Meffre
-
依托单位:
Loss of B Cell Tolerance in Primary Immune Deficiency
-
批准号:9358754
-
项目类别:
-
资助金额:$47.3万
-
财政年份:2004
-
负责人:Eric Meffre
-
依托单位:
Loss of B Cell Tolerance in Primary Immune Deficiency
-
批准号:10218002
-
项目类别:
-
资助金额:$44.81万
-
财政年份:2004
-
负责人:Eric Meffre
-
依托单位:
Loss of B Cell Tolerance in Primary Immunodeficiencies
-
批准号:6847373
-
项目类别:
-
资助金额:$21.45万
-
财政年份:2004
-
负责人:Eric Meffre
-
依托单位:
Loss of B Cell tolerance in Primary Immune Deficiency
-
批准号:8381518
-
项目类别:
-
资助金额:$52.89万
-
财政年份:2004
-
负责人:Eric Meffre
-
依托单位:
海外基金